Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In all, 200 healthy, sexually active, fertile male candidates will be assigned 100 in silodosin group and 100 in placebo group. Males using other contraceptive methods will be excluded. Follow up data of total spermatozoa per ejaculate, semen volume and Post-ejaculation urinalysis after 2, 6 and 12 weeks of the studied groups will be recorded. The various side effects reported in the study groups after 12 weeks from the start of the study will be recorded.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sildosin arm | Active Comparator | Oral intake of sildosin |
|
| Placebo arm | Placebo Comparator | Oral intake of placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oral intake of sildosin | Drug | Oral intake of sildosin in male non hormonal contraception |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Pregnancy rate in people treated with sildosin as a male contraceptive | Pregnancy rate in people treated with sildosin as a male contraceptive treatment | 3 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Male
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Oral intake of placebo |
| Other |
Intake of placebo to compare effecacy of other group |
|